Ipamorelin

Ipamorelin is a synthetic growth hormone-releasing peptide (GHRP) that functions as a highly selective agonist of the ghrelin receptor (also known as the growth hormone secretagogue receptor, GHSR-1a). Its mechanism of action can be summarized as follows:

• Ghrelin Receptor Activation: Ipamorelin binds specifically to and activates the GHSR-1a in the pituitary gland and hypothalamus. This mimics the action of the endogenous hormone ghrelin, which is a natural stimulator of growth hormone (GH) release.
• Stimulates GH Secretion: Upon activating GHSR-1a, Ipamorelin signals the somatotroph cells in the anterior pituitary to increase both the synthesis and pulsatile release of GH. This occurs via a G-protein coupled receptor pathway, leading to increased intracellular calcium and subsequent exocytosis of GH.
• High Selectivity: A key characteristic of Ipamorelin is its high selectivity for GH release. Unlike some other GHRPs, it does not significantly stimulate the release of other pituitary hormones such as adrenocorticotropic hormone (ACTH), cortisol, prolactin, or luteinizing hormone (LH). This selective action minimizes potential side effects associated with broader hormonal fluctuations.
• Non-apetitive: Unlike ghrelin itself, Ipamorelin does not appear to significantly stimulate appetite, a common side effect of ghrelin mimetics, making it a potentially more favorable compound for specific research applications.

This targeted and selective mechanism makes Ipamorelin a valuable tool for research into growth hormone regulation and its physiological effects without confounding influences from other hormones.

Ipamorelin has been investigated in various **preclinical and early-phase clinical research settings** primarily for its potential in conditions related to growth hormone deficiency and its broader metabolic and physiological effects. Research focus includes:

• Growth Hormone Secretion Enhancement: Studies explore its ability to induce a sustained physiological release of GH, evaluating its potency and selectivity compared to other GHRPs.
• Body Composition Modulation: Investigations into its impact on lean muscle mass, fat metabolism, and overall energy balance in animal models and early human studies.
• Bone Health: Research into its potential to stimulate osteoblast activity and enhance bone mineral density, relevant for conditions like osteoporosis.
• Gastrointestinal Motility: Early trials have explored its effects on accelerating gastrointestinal recovery and preventing postoperative ileus, highlighting its action on ghrelin receptors in the gut.
• Safety and Pharmacokinetics: Extensive research focuses on understanding its absorption, distribution, metabolism, excretion, and overall safety profile in various research models.

It's important to note that while initial human studies explored its safety and pharmacokinetics, Ipamorelin is generally classified as a **research chemical** for laboratory use due to its investigational status and lack of regulatory approval for therapeutic applications.

For optimal stability and preservation of Ipamorelin, observe the following recommendations:

• Storage: Store lyophilized powder at -20°C to -80°C (long-term) or 2°C to 8°C (short-term, for up to 2-4 weeks), away from light and moisture.
• Reconstitution: Reconstitute with sterile, deionized water or a suitable solvent as per specific experimental protocols. Avoid repeated freeze-thaw cycles.
• Handling: Handle under aseptic conditions to prevent contamination. Use appropriate personal protective equipment (PPE), including gloves and eye protection.
• Stability: Once reconstituted, solutions should be stored at 2°C to 8°C and used within a short period, typically 24-72 hours, depending on the solvent and concentration. Long-term storage of reconstituted solutions is not recommended.
• Disposal: Dispose of Ipamorelin and any waste materials in accordance with local and institutional hazardous waste regulations.

Strict adherence to these guidelines will help maintain the integrity and purity of the compound for research applications.

For more detailed information on Ipamorelin and its research applications, please refer to the following scientific literature and review articles, primarily from preclinical studies:

• Growth Hormone Secretagogues: Best Pract Res Clin Endocrinol Metab, PMID: 28841020 (Comprehensive review of GH secretagogues)
• Ipamorelin, a new growth hormone-releasing peptide, for the prevention of postoperative ileus: Eur J Surg Suppl, PMID: 11182582 (Early research on Ipamorelin's effects beyond GH)
• Growth hormone-releasing peptides: Eur J Endocrinol, PMID: 11211756 (Review of GHRPs, including Ipamorelin's class)
• Growth hormone-releasing peptides and their impact on body composition: Curr Pharm Des, PMID: 22692297 (Review on GHRPs and body composition)
• A phase 2 study of Ipamorelin for the prevention of postoperative ileus in abdominal surgery: World J Surg, PMID: 12479764 (Specific human clinical trial on Ipamorelin)
• PubChem Compound Summary: Ipamorelin (CID 9831659)

*(Note: References are primarily focused on preclinical and mechanistic studies, reflecting Ipamorelin's status as a research compound.)*

This product, Ipamorelin, is sold exclusively for **research and development purposes**. It is classified as a research chemical and is **not a drug, food, or cosmetic**. It has not been evaluated or approved by the FDA or any other regulatory authority for safety, efficacy, or any other use in humans or animals. By purchasing this product, the user acknowledges and agrees to comply with all applicable local, national, and international laws and regulations regarding the handling, storage, and use of research compounds. Any use of this product for purposes other than legitimate scientific research is strictly prohibited and may lead to severe legal and health consequences.